Mentice Year-end Report Q4, Oct - Dec 2022
READ MORE
REGISTER
REGISTER FOR THE MENTICE YEAR-END REPORT Q4 OCT - DEC 2022 EARNINGS CALL
READ MORE
REGISTER

Mentice receives an initial order of USD 1.93million for simulation solutions and development services from a global medtech company

Wednesday, June 29, 2022

Sweden-Gothenburg,  June 29, 2022 (https://news.cision.com/mentice-ab).

Mentice, Gothenburg (STO: MNTC), a world leader in simulation solutions for image-guided interventional therapies, announced today that a global healthcare technology leader, has signed an agreement to acquire Mentice VIST® simulation solutions and development services, in an initial order of USD 1.93 million. The initial order includes the development services and 10 simulation solutions for delivery in 2022 raising to an additional intention of 150 simulation solutions over 3 years.

"This agreement is, of course, an important commitment from one of the world’s largest medical device manufacturers though also to drive proficiency for physicians with aim of ultimately improving patient outcomes" says Göran Malmberg, CEO and Group President for Mentice, "this continues to underline our position as the leading provider of performance solutions for Image guided interventional therapies" Malmberg continues. 

For further information, please contact:
Göran Malmberg, CEO, Mentice
Email: 
goran.malmberg@mentice.com

Tel US: +1 (312) 860 5610
Tel Sweden: +46 (0) 703 09 22 22

About Mentice 

Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventionaltherapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com

This information is information that Mentice AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person, at 29th of June 08.00 CET, 2022.  

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC

Certified Adviser| FNCA Sweden AB, phone +46 8 528 00 399

Mentice Bokslutskommuniké, Jan - Dec 2022
LÄS MER
REGISTRERA DIG FÖR MENTICE BOKSLUTSKOMMUNIKE OKT - DEC 2022 WEBCAST
LÄS MER

Mentice receives an initial order of USD 1.93million for simulation solutions and development services from a global medtech company

Wednesday, June 29, 2022

Sweden-Gothenburg,  June 29, 2022 (https://news.cision.com/mentice-ab).

Mentice, Gothenburg (STO: MNTC), a world leader in simulation solutions for image-guided interventional therapies, announced today that a global healthcare technology leader, has signed an agreement to acquire Mentice VIST® simulation solutions and development services, in an initial order of USD 1.93 million. The initial order includes the development services and 10 simulation solutions for delivery in 2022 raising to an additional intention of 150 simulation solutions over 3 years.

"This agreement is, of course, an important commitment from one of the world’s largest medical device manufacturers though also to drive proficiency for physicians with aim of ultimately improving patient outcomes" says Göran Malmberg, CEO and Group President for Mentice, "this continues to underline our position as the leading provider of performance solutions for Image guided interventional therapies" Malmberg continues. 

For further information, please contact:
Göran Malmberg, CEO, Mentice
Email: 
goran.malmberg@mentice.com

Tel US: +1 (312) 860 5610
Tel Sweden: +46 (0) 703 09 22 22

About Mentice 

Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventionaltherapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com

This information is information that Mentice AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person, at 29th of June 08.00 CET, 2022.  

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC

Certified Adviser| FNCA Sweden AB, phone +46 8 528 00 399